In the present study, we evaluated the expression of TSPY and EEF1A, with references to prostatic tumor and normal basal cell biomarkers, among non-cancer prostate (control), latent prostate cancer (LPCa) and clinical prostate cancer (CPCa) using immunohistochemistry and specific antibodies against TSPY and EEF1A. This evidence concerns the gene TSPY1 and prostate neoplasm.